The increased prevalence of antifungal drug resistance and emergence of multidrug-resistant species such as Candida auris represent a global public health threat. By mapping drug susceptibility responses of experimentally evolved C. auris across diverse antifungals, we found trends of cross-resistance (XR) and collateral sensitivity (CS) and show that CS can reduce resistance development through drug cycling and combination therapy, providing a promising direction for future research.